Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.
BeyondSpring Inc. (NASDAQ: BYSI) generates a steady flow of news centered on the clinical and regulatory progress of its lead asset, Plinabulin, and on its corporate and financing activities. As a clinical-stage biopharmaceutical company focused on cancer, BeyondSpring’s updates often highlight new data from phase 2 and phase 3 trials in non-small cell lung cancer (NSCLC) and other tumor types, as well as mechanistic findings related to Plinabulin’s dendritic cell maturation and immune-modulating properties.
News releases frequently cover results from major oncology conferences and journals. Examples include presentations at the American Society of Clinical Oncology (ASCO), the IASLC/ASCO North America Conference on Lung Cancer (NACLC), the Society for Immunotherapy of Cancer (SITC), Immuno-Oncology 360°, and ESMO Asia, along with peer-reviewed publications in outlets such as Lancet Respiratory Medicine and Med (Cell Press). These communications describe outcomes from the DUBLIN‑3 phase 3 trial, the 303 and 302 phase 2 studies, and basket trials combining Plinabulin with checkpoint inhibitors, chemotherapy, and radiation.
Investors following BYSI news can also expect regular financial updates, including quarterly results, cash position, and operating expense trends, as well as 10‑K filing announcements. Corporate news items address equity financings, such as registered offerings of ordinary shares, and strategic transactions involving BeyondSpring’s equity stake in SEED Therapeutics, a targeted protein degradation company co-founded by BeyondSpring.
For market participants tracking oncology pipelines, the BYSI news stream provides insight into Plinabulin’s clinical performance, safety profile, biomarker research, and planned registrational strategies, including the company’s intention to advance confirmatory trials like DUBLIN‑4. Bookmarking the news page allows readers to monitor how new data, conference presentations, and SEC-referenced announcements may influence the development trajectory of Plinabulin and BeyondSpring’s broader strategy.
BeyondSpring (NASDAQ: BYSI) has announced a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation will focus on the 303 Study, an investigator-initiated study supported by Merck and BeyondSpring, examining the combination of Pembrolizumab, Plinabulin, and Docetaxel in second and third-line non-small cell lung cancer (NSCLC) patients who progressed on PD-1/PD-L1 inhibitors.
The presentation, titled "Phase 2 Study of Pembrolizumab plus Plinabulin and Docetaxel for Patients with Metastatic NSCLC," will be delivered on May 31, 2025, from 1:30 PM to 4:30 PM CDT at the McCormick Place Convention Center. The study focuses on efficacy and safety results related to immune re-sensitization in patients who progressed after first-line immune checkpoint inhibitor therapy.
BeyondSpring (NASDAQ: BYSI), a global clinical-stage biopharmaceutical company focused on innovative cancer therapies, has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024. The report was submitted to the SEC on March 27, 2025.
The annual report, containing audited consolidated financial statements, is accessible through the SEC website and BeyondSpring's corporate website under the Investors section. The company offers shareholders the option to request free hard copies of the annual report through their Investor Relations department in Florham Park, NJ.
BeyondSpring (NASDAQ: BYSI) has announced the sale of a portion of its Series A-1 Preferred Shares in SEED Therapeutics for $35.4 million. After the transaction, BeyondSpring will retain approximately 14.4% ownership in SEED. The proceeds will fund late-stage clinical trials of Plinabulin, the company's lead anti-cancer agent.
Plinabulin has shown promising results across multiple studies: The DUBLIN-3 phase 3 study demonstrated significant overall survival benefits in NSCLC patients; the 303 Study showed 89.3% disease control rate and 8.6 months median PFS in NSCLC patients; and the 302 Study began enrollment for first-line ES-SCLC treatment.
SEED Therapeutics, co-founded with Eli Lilly in 2020, focuses on Targeted Protein Degradation technology and recently completed a Series A-3 financing led by Eisai at a $100 million pre-money valuation.
BeyondSpring (NASDAQ: BYSI) presented updated Phase 2 trial results for a triple combination therapy in non-small cell lung cancer (NSCLC) patients who progressed after PD-1/PD-L1 inhibitor treatment. The study of 30 patients, with a median follow-up of 11.5 months, showed promising results with a disease control rate of 89.3% and median progression-free survival of 8.6 months. The treatment combination of pembrolizumab plus plinabulin/docetaxel achieved a confirmed overall response rate of 21.1% and median duration of response of 11.4 months. The therapy was generally well-tolerated, with 46.7% of patients experiencing grade 3 or higher treatment-related adverse effects.
BeyondSpring (NASDAQ: BYSI) presented final data on the DUBLIN-3 Phase 3 study at ESMO Congress 2024, showing significant improvements in overall survival, progression-free survival, and objective response rate for the plinabulin/docetaxel combination in 2L/3L EGFR wild-type NSCLC patients. The combination demonstrated a favorable benefit/risk ratio over docetaxel alone, including:
1. >80% relative reduction in Grade 4 neutropenia
2. Reduced use of G-CSF
3. Improved quality of life
4. Significant reduction in cycle-adjusted serious adverse events
The study suggests this combination could be a new option for second or third-line NSCLC patients without driver mutation, addressing an unmet medical need.
BeyondSpring (NASDAQ: BYSI) presented interim phase 2 data on the 303 Study at ESMO Congress 2024, evaluating a triple combination regimen of pembrolizumab plus plinabulin/docetaxel in 2L/3L NSCLC patients after progression on 1L PD-1/L1 inhibitors. The study showed promising results:
- Median PFS of 8.63 months (compared to historical 3-4 months)
- Disease Control Rate of 89.5%
- Confirmed ORR of 21.1%
- 6-month PFS rate: 67.1%; 12-month PFS rate: 49.2%
- Median Duration of Response: 11.40 months
The combination was well-tolerated, with 52.6% of patients experiencing grade 3 or higher treatment-related adverse effects. No treatment-related deaths were reported. The study is ongoing at Peking Union Medical College Hospital, aiming to enroll 47 patients total.
BeyondSpring Inc. (NASDAQ: BYSI) presented final Phase 3 data of its lead anti-cancer asset Plinabulin at ISLAC 2024 World Conference on Lung Cancer. The DUBLIN-3 study showed statistically significant and clinically meaningful efficacy data for Plinabulin plus Docetaxel vs. Docetaxel alone in EGFR wild-type NSCLC patients after progression on platinum-based therapy. Key findings include:
- Improved overall survival (OS) with HR=0.82
- Better progression-free survival (PFS) with HR=0.79
- Nearly doubled objective response rate (ORR)
- Doubled 24-month and 36-month OS rates
- 82% reduction in Grade 4 neutropenia
The combination showed a favorable benefit/risk ratio and could be considered as a new treatment option for this population with high unmet medical needs.
BeyondSpring Inc. (NASDAQ: BYSI) announces upcoming presentations showcasing its lead anti-cancer asset, Plinabulin, at two major oncology conferences. At the 2024 World Conference on Lung Cancer on September 9, an oral presentation will reveal final efficacy data of Plinabulin and docetaxel combination vs. docetaxel from the Dublin-3 phase 3 study in EGFR wild-type 2L/3L non-small cell lung cancer (NSCLC).
Additionally, at the ESMO Congress 2024 on September 14, two poster presentations will cover the Dublin-3 study safety outcome and the 303 Study, an investigator-initiated study supported by Merck in 2L/3L NSCLC patients who failed PD-1/PD-L1 inhibitors. These presentations highlight BeyondSpring's ongoing efforts in developing innovative cancer therapies, particularly for lung cancer patients.
SEED Therapeutics has announced a strategic research collaboration with Eisai Co., to discover and develop novel molecular glue degraders for neurodegeneration and oncology targets. SEED is entitled to receive up to $1.5 billion in upfront and milestone payments, plus tiered royalties. Concurrently, SEED has launched a Series A-3 financing with a first close of $24 million led by Eisai, with a second close targeted for Q4 2024.
The collaboration leverages Eisai's expertise in neurodegeneration and cancer. SEED will lead preclinical discovery activities, while Eisai will have exclusive rights to develop and commercialize resulting compounds. The financing will advance SEED's clinical development of internal programs, including an oral RBM39 Degrader for cancer and a Tau degrader for Alzheimer's disease, as well as expand its TPD platform and pipeline.